Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa

Immutep (IMMP) and Dr. Reddy’s Laboratories (RDY) announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The terms of the licensing agreement provide Immutep with significant milestones and preserves its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy’s in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan. Additionally, as per the agreement, Immutep will receive from Dr. Reddy’s an upfront payment of USD 20 million. It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million, plus double-digit royalties on commercial sales in these markets.